Clinical Trials in Fremantle, Australia
5 recruiting
Showing 1–11 of 11 trials
Recruiting
Phase 3
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma (CSCC)
Regeneron Pharmaceuticals369 enrolled49 locationsNCT06585410
Recruiting
Phase 3
Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin
Heart Failure
AstraZeneca11,300 enrolled928 locationsNCT06677060
Recruiting
The Australian HCV Point-of-Care Testing Program
Hepatitis C
Kirby Institute60,000 enrolled69 locationsNCT05042544
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
Prurigo Nodularis
Incyte Corporation330 enrolled121 locationsNCT06516965
Recruiting
Phase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Hidradenitis Suppurativa (HS)
Incyte Corporation600 enrolled330 locationsNCT06855498
Recruiting
Phase 3
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
Alopecia Areata
AbbVie1,500 enrolled267 locationsNCT06012240
Recruiting
Phase 2
A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
Atopic Dermatitis
Pfizer340 enrolled97 locationsNCT05995964
Recruiting
Phase 1
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
Alopecia AreataVitiligo
Dren Bio80 enrolled20 locationsNCT06602232
Recruiting
Clinical Utility and Gait Analysis of NextAR System AUS
Total Knee Arthroplasty
Medacta International SA100 enrolled1 locationNCT05863741
Recruiting
Phase 3
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
CarcinomaNon-Small-Cell Lung
AstraZeneca324 enrolled283 locationsNCT05261399
Recruiting
Not Applicable
ETHOS ENGAGE: Enhancing Treatment of Hepatitis C in Opioid Substitution Settings
Hepatitis C
Kirby Institute6,000 enrolled29 locationsNCT03685045